NASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free QURE Stock Alerts $4.92 -0.15 (-2.96%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.80▼$5.1450-Day Range$4.39▼$5.4152-Week Range$4.25▼$22.48Volume730,215 shsAverage Volume581,915 shsMarket Capitalization$238.87 millionP/E RatioN/ADividend YieldN/APrice Target$26.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get uniQure alerts: Email Address uniQure MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside442.0% Upside$26.67 Price TargetShort InterestBearish6.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.22Based on 20 Articles This WeekInsider TradingSelling Shares$339,845 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.45) to ($4.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector645th out of 925 stocksPharmaceutical Preparations Industry306th out of 430 stocks 3.4 Analyst's Opinion Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageuniQure has only been the subject of 3 research reports in the past 90 days.Read more about uniQure's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.72% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in uniQure has recently increased by 15.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QURE. Previous Next 1.5 News and Social Media Coverage News SentimentuniQure has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for uniQure this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows6 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $339,845.00 in company stock.Percentage Held by InsidersOnly 4.74% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($4.45) to ($4.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about uniQure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About uniQure Stock (NASDAQ:QURE)uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Read More QURE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QURE Stock News HeadlinesMay 12, 2024 | americanbankingnews.comMizuho Cuts uniQure (NASDAQ:QURE) Price Target to $6.00May 12, 2024 | americanbankingnews.comuniQure Forecasted to Earn FY2027 Earnings of $0.67 Per Share (NASDAQ:QURE)May 12, 2024 | Colonial Metals (Ad)Collapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.May 11, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on uniQure's Q2 2024 Earnings (NASDAQ:QURE)May 10, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Stock Rating Reaffirmed by HC WainwrightMay 9, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for uniQure (NASDAQ:QURE) Reduced by AnalystMay 7, 2024 | investorplace.comQURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 12, 2024 | Colonial Metals (Ad)Collapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.May 4, 2024 | americanbankingnews.comuniQure (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by AnalystsFebruary 28, 2024 | globenewswire.comuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressJuly 17, 2023 | seekingalpha.comuniQure: The AMT-130 ReadoutMay 22, 2023 | seekingalpha.comMarket Is Still Not Pricing In The FDA And EU EMA Approvals For uniQureMay 20, 2023 | seekingalpha.comuniQure: Financials And Pipeline Signal A Promising Outlook For InvestorsFebruary 7, 2022 | globenewswire.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswireFebruary 7, 2022 | finance.yahoo.comuniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseFebruary 5, 2022 | washingtonpost.comWith CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington PostFebruary 4, 2022 | finance.yahoo.comGlobal Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo FinanceFebruary 4, 2022 | marketscreener.comEAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B - Marketscreener.comFebruary 4, 2022 | axios.com5 unique date ideas in NW Arkansas - AxiosFebruary 4, 2022 | reuters.comAmazon has a unique inflation problem - ReutersFebruary 3, 2022 | chicago.suntimes.comBears hope Justin Fields ‘skyrockets’ — but his rookie struggles weren’t unique - Chicago Sun-TimesFebruary 3, 2022 | washingtonpost.comTurkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington PostFebruary 3, 2022 | nj.comUnique soap shop franchise to make N.J. debut - NJ.comFebruary 2, 2022 | forbes.comLooking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - ForbesFebruary 2, 2022 | bbc.comDeliberate infections give unique Covid insight - BBC NewsJanuary 31, 2022 | pymnts.comWhat Makes the UE’s Digital Markets Act Unique - pymnts.comSee More Headlines Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/12/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QURE CUSIPN/A CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees480Year FoundedN/APrice Target and Rating Average Stock Price Target$26.67 High Stock Price Target$50.00 Low Stock Price Target$6.00 Potential Upside/Downside+442.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($6.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-308,480,000.00 Net Margins-1,562.22% Pretax Margin-1,542.31% Return on Equity-121.60% Return on Assets-34.76% Debt Debt-to-Equity Ratio0.70 Current Ratio9.39 Quick Ratio8.68 Sales & Book Value Annual Sales$15.84 million Price / Sales15.08 Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book1.63Miscellaneous Outstanding Shares48,550,000Free Float46,248,000Market Cap$238.87 million OptionableOptionable Beta0.98 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Matthew Craig Kapusta (Age 52)CEO & Executive Director Comp: $1.02MMr. Christian Klemt (Age 51)CFO, Principal Financial Officer & GM of Amsterdam Site Comp: $575.46kMr. Pierre Caloz (Age 52)Chief Operating Officer Comp: $882.59kDr. Tamara Tugal Ph.D.MBA, Business Development DirectorMs. Carla PoulsonInterim Chief People and Culture OfficerMs. Maria E. Cantor (Age 56)Chief Corporate Affairs Officer Comp: $491.12kDr. Amin Abujoub Ph.D.Chief Quality OfficerDr. Walid Abi-Saab M.D. (Age 59)Chief Medical Officer Eileen SawyerVice President of Global Medical AffairsMore ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSPuma BiotechnologyNASDAQ:PBYIAC ImmuneNASDAQ:ACIUZevra TherapeuticsNASDAQ:ZVRAConduit PharmaceuticalsNASDAQ:CDTView All CompetitorsInsiders & InstitutionsCovestor LtdBought 27,267 shares on 5/11/2024Ownership: 0.111%Vanguard Group Inc.Bought 109,740 shares on 5/10/2024Ownership: 2.242%Acadian Asset Management LLCBought 350,291 shares on 5/10/2024Ownership: 1.282%BNP Paribas Financial MarketsBought 30,054 shares on 5/1/2024Ownership: 1.540%Mirae Asset Global Investments Co. Ltd.Bought 66,958 shares on 5/1/2024Ownership: 0.329%View All Insider TransactionsView All Institutional Transactions QURE Stock Analysis - Frequently Asked Questions Should I buy or sell uniQure stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" QURE shares. View QURE analyst ratings or view top-rated stocks. What is uniQure's stock price target for 2024? 7 analysts have issued 1-year price targets for uniQure's stock. Their QURE share price targets range from $6.00 to $50.00. On average, they predict the company's stock price to reach $26.67 in the next twelve months. This suggests a possible upside of 442.0% from the stock's current price. View analysts price targets for QURE or view top-rated stocks among Wall Street analysts. How have QURE shares performed in 2024? uniQure's stock was trading at $6.77 at the beginning of the year. Since then, QURE shares have decreased by 27.3% and is now trading at $4.92. View the best growth stocks for 2024 here. When is uniQure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our QURE earnings forecast. How were uniQure's earnings last quarter? uniQure (NASDAQ:QURE) released its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.53) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.01. The biotechnology company earned $6.69 million during the quarter, compared to analysts' expectations of $3.20 million. uniQure had a negative trailing twelve-month return on equity of 121.60% and a negative net margin of 1,562.22%. What ETFs hold uniQure's stock? ETFs with the largest weight of uniQure (NASDAQ:QURE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).iShares Genomics Immunology and Healthcare ETF (IDNA). What is Matthew Kapusta's approval rating as uniQure's CEO? 8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE). Who are uniQure's major shareholders? uniQure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.24%), BNP Paribas Financial Markets (1.54%), Acadian Asset Management LLC (1.28%), Privium Fund Management B.V. (1.21%), Mirae Asset Global Investments Co. Ltd. (0.33%) and Covestor Ltd (0.11%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Rachelle Suzanne Jacques, Ricardo Dolmetsch and Robert Gut. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QURE) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking: One AI startup's revenue could surge 4,735%Manward PressElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchYou need to know these two things about AI stocks ASAP…InvestorPlace[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
